



2016-2017 POCC Lecture Series

May 25, 2017, 8:00 PM

The Teva Lecture at POCC


Dr. Sean P. Brown

Amgen

***Interdiction at a Protein-Protein Interface:
Structure-Based Design of Mcl-1 Inhibitors***

Carolyn Hoff Lynch Lecture Hall
Chemistry Building, University of Pennsylvania

The Philadelphia
Organic Chemist's Club



POCClub.org

To join us for dinner before the lecture please contact POCC's secretary Thomas Razler (thomas.razler@bms.com) at least one week ahead of time.

Sean P. Brown completed his B.S. in Chemistry in 1998 at the University of California at Davis performing research under the direction of Professor Mark J. Kurth. He then worked at the biotechnology company Chiron until 2000 after which he began his Ph.D. with Professor David MacMillan at Caltech designing enantioselective organocatalytic transformations. Upon completion of his Ph.D. in 2005, Sean joined Amgen where he is currently a Principle Scientist. Sean's research efforts at Amgen have been focused toward innovative approaches to previously thought to be "undruggable" target classes.

Abstract: Targeting disruption of Mcl-1's protein-protein interaction to induce tumor cell death was previously thought to be "un-druggable," due to the high affinities of Mcl-1 to the pro-apoptotic Bcl-2 proteins and lack of a small molecule binding pocket. This presentation will describe the convergence of ligand/protein structural information and small molecule conformational analysis applied to the optimization of a small molecule high-throughput screening hit to this now "druggable" target.